Dual therapy with allicin and metformin provides superior cardioprotection against doxorubicin-induced cardiotoxicity in rats compared to monotherapy.

ABSTRACT:

Background

Doxorubicin is a widely used chemotherapeutic agent; however, its clinical utility is limited by dose-dependent cardiotoxicity. Existing cardioprotective strategies are insufficient, showing that there is a need for safer and more effective alternatives.

Objectives

This study evaluated the cardioprotective effects of metformin and allicin, individually and in combination, against doxorubicin-induced cardiotoxicity in rats.

Methods

Fifty adult male Wistar albino rats were randomized into five groups (n = 10 each): The control group was administered normal saline (2 mL/kg, intraperitoneally, on days 7, 14, and 21); the DOX-only group received doxorubicin (6 mg/kg, intraperitoneally, on days 7, 14, and 21; cumulative dose 18 mg/kg); the DOX + Allicin group was

SUBMITTER: Mojamel M 

PROVIDER: S-EPMC12827077 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature